Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX-Fc fusion protein: A randomized trial-Reference-Cited by-同舟云学术

Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX-Fc fusion protein: A randomized trial

Published:2019-03-23 Issue:2 Volume:3 Page:268-276
ISSN:2475-0379
Container-title:Research and Practice in Thrombosis and Haemostasis
language:en
Short-container-title:Res Pract Thromb Haemost

Author:

Escuriola Ettingshausen Carmen¹,Hegemann Inga²,Simpson Mindy L.³,Cuker Adam⁴,Kulkarni Roshni⁵,Pruthi Rajiv K.⁶,Garly May-Lill⁷,Meldgaard Rikke M.⁷,Persson Paula⁷,Klamroth Robert⁸

Affiliation:

1. Hämophilie Zentrum Rhein Main (HZRM); Mörfelden-Walldorf Germany

2. Division of Haematology; Zürich University Hospital; Zürich Switzerland

3. Pediatric Hematology/Oncology; Rush University Medical Center; Chicago IL USA

4. Perelman School of Medicine; University of Pennsylvania; Philadelphia PA USA

5. Department of Pediatrics and Human Development; Michigan State University; East Lansing MI USA

6. Hematology/Internal Medicine; Mayo Clinic; Rochester MN USA

7. Novo Nordisk A/S; Søborg Denmark

8. Department for Internal Medicine; Vascular Medicine and Haemostaseology; Vivantes Klinikum; Berlin Germany

Funder

Novo Nordisk

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/rth2.12192/fullpdf

Reference29 articles.

1. Changing paradigm of prophylaxis with longer acting factor concentrates;Carcao;Haemophilia,2014

2. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia;Manco-Johnson;N Engl J Med,2007

3. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study);Gringeri;J Thromb Haemost,2011

4. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B;Iorio;Cochrane Database Syst Rev,2011

5. Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH;Iorio;J Thromb Haemost,2017

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biodistribution of recombinant factor IX, extended half-life recombinant factor IX Fc fusion protein, and glycoPEGylated recombinant factor IX in hemophilia B mice;Blood Coagulation & Fibrinolysis;2023-07-17

2. Efficacy of rFIXFc versus N9-GP Prophylaxis in Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PARADIGM 2 Trials;Journal of Blood Medicine;2023-07

3. Current factor IX replacement options for hemophilia B and the challenges ahead;Expert Opinion on Pharmacotherapy;2023-03-29

4. Regulatory Considerations Toward Orphan Drug Designation and Orphan Drug Exclusivity in the United States and European Union: Structural Similarity, Clinical Superiority/Significant Benefit, and Case Studies;Therapeutic Innovation & Regulatory Science;2022-11-18

5. Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B;Cochrane Database of Systematic Reviews;2021-08-18